Factor ii and fibrinogen for treatment of haemostatic disorders
AssigneeMedImmune, LLC
InventorsAnn Eva Monica Lõvgren, Kenny M. Hansson
Life of this patent
Estimating the term…
Abstract
The present invention relates to normalizing impaired haemostasis comprising administering a clotting factor treatment selected from the group consisting of (1) FII; (2) PCC; and (3) a three factor combination of FH, FX and FVIIa. The clotting factor treatment can be administered in combination with fibrinogen. The clotting factor(s) can be recombinant human clotting factor(s).
Claims23
A method of normalizing impaired haemostasis in a mammal in need thereof comprising administering a clotting factor treatment selected from the group consisting of (1) FII, (2) a combination of FII, FVIIa, and FX, (3) fibrinogen and a combination of FII, FVIIa, and FX, and (4) fibrinogen and FII.
A method of increasing maximum clot firmness (MCF) in a mammal having impaired haemostasis, comprising administering a clotting factor treatment selected from the group consisting of (1) FII, (2) a combination of FII, FVIIa, and FX, (3) fibrinogen and a combination of FII, FVIIa, and FX, and (4) fibrinogen and FII.
A method of reducing coagulation time (CT) in a mammal having impaired haemostasis, comprising administering a clotting factor treatment selected from the group consisting of (1) FII, (2) a combination of FII, FVIIa, and FX, (3) fibrinogen and a combination of FII, FVIIa, and FX, and (4) fibrinogen and FII.
A method of improving thrombin generation in a mammal having impaired haemostasis, comprising administering a clotting factor treatment selected from the group consisting of (1) FII, (2) a combination of FII, FVIIa, and FX, (3) fibrinogen and a combination of FII, FVIIa, and FX, and (4) fibrinogen and FII.
(canceled)
10-11. (canceled)
(canceled)
Dependencies are inferred from the claim text.